Spondyloarthropathies: Targeted therapy for psoriatic arthritis

Nature Reviews Rheumatology

Volumn 5, Issue 5, 2009, Pages 241-242

  Gladman, Dafna D ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

DRUG DELIVERY SYSTEM; DRUG RESISTANCE; DRUG TOLERANCE; HUMAN; NOTE; PHASE 3 CLINICAL TRIAL; PSORIATIC ARTHRITIS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE; DRUG TOLERANCE; HUMANS; TREATMENT OUTCOME;

EID: 67650354853     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2009.76     Document Type: Article

References (10)

1. Gladman, D. D. Psoriatic arthritis. Dermatol. Ther. 22, 40–55 (2009).
2. Gottlieb, A. et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373, 633–640 (2009).
3. Soriano, E. R. & McHugh, N. J. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J. Rheumatol. 33, 1422–1430 (2006).
4. Ribbens, C. et al. increased synovial fluid levels of interleukin-12, sCD25 and sTnF-Rii/sTnF-Ri ratio delineate a cytokine pattern characteristic of immune arthropathies. Eur. Cytokine Netw. 11, 669–676 (2000).
5. Hueber, A. J. & McInnes, I. B. Immune regulation in psoriasis and psoriatic arthritis—recent developments. Immunol. Lett. 114, 59–65 (2007).
6. Ravindran, V., Scott, D. L. & Choy, E. H. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Ann. Rheum. Dis. 67, 855–859 (2008).
7. Nair, R. P. et al. Genome-wide scan reveals association of psoriasis with iL-23 and nF-κB pathways. Nat. Genet. 41, 199–204 (2009).
8. Hüffmeier, U. et al. Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis. J. Invest. Dermatol. 129, 355–358 (2009).
9. Rahman, P. et al. Association of interleukin-23R variants with psoriatic arthritis. J. Rheumatol. 36, 137–140 (2009).
10. Krueger, G. G. et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N. Engl. J. Med. 356, 580–592 (2007).